Tardive dyskinesia, a permanent neurological disorder characterized by involuntary facial movements caused by the contracting of facial muscles, has been decisively linked to gastrointestinal drug Reglan, causing almost a hundred users to file a Reglan lawsuit against the company responsible in order to hopefully collect a settlement that can pay for the high cost of living with a permanent disorder or one of the other side effects of the drug.
Reglan works to aid digestion by stimulating the muscles in the stomach and intestine to contract in order to move food more quickly through the digestive system. However, its power to make muscles contract seems to have the tendency to spread to areas of the body where it is not necessarily wanted. Side effects that are normal with Reglan and do not indicate a problem include nausea, diarrhea, headache, dizziness, and lethargy.
Symptoms of a Reglan allergic reaction, which can be serious and requires immediate medical attention, include rash, swelling of the mouth, and tightness in the chest. The most dangerous side effects of Reglan only happen to a small percentage of Reglan users, but they can be fatal. These include central nervous system disorders such as convulsive seizures and hallucinations, as well as neuroleptic malignant syndrome, which is characterized by hyperthermia, muscular rigidity, and autonomic instability – all of which are also symptoms of a panic attack, a much more common and non-fatal occurrence.
People who are seeking compensation in their lawsuits against Reglan are looking for a settlement that will help them pay for not only the money they have lost battling what could be a permanent affliction, but also reimburse them for their pain and suffering. Although it is not yet clear what kind of settlement plaintiffs should expect to receive, what is clear is that no one should put their life and comfort on the line just to take a certain medication. Victims suffering from the side effects of Reglan should call an experienced Reglan lawyer immediately.
No comments:
Post a Comment